What are the Real Indirect Costs Associated with Multiple Myeloma: Model Patient Analysis From Slovak Republic

Babela, R.; Rafayova, M; Hurna, J

doi:10.1016/j.jval.2018.04.158

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, it does not estimate the cost of work absenteeism incurred by both the patient and caregivers, lost work productivity due to illness or premature death, the cost to travel to and from appointments, cost of supportive medications not provided on the clinical trial or by provincial or private insurance. A recent publication by a group in Slovakia reported indirect costs of MM to be €133 000 in the first year after initial diagnosis 37 . The societal and indirect costs of MM therapies are likely significant for Canadians as well, but these costs have not previously been described in Canada and represent an opportunity for future exploration.…”

Section: Discussionmentioning

confidence: 99%

A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma

Monteith

Venner

Cheung

et al. 2021

European J of Haematology

View full text Add to dashboard Cite

Background The prevalence of multiple myeloma is increasing and there is a need to evaluate escalating therapy costs (Canadian Cancer Statistics A, 2020). The MYX.1 phase II trial showed that high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone (wKCD) is efficacious in relapsed and refractory disease. We conducted a descriptive cost analysis, from the perspective of the Canadian public healthcare system, using trial data. Methods The primary outcome was the mean total cost per patient. Resource utilization data were collected from all 75 trial patients over a trial time horizon. Costs are presented in Canadian dollars (2020). Results The cost of treatment was calculated from the time of patient (pt) enrollment until the second data lock. The mean total cost was $203 336.08/pt (range $17 891.27‐$505 583.55) Canadian dollars (CAD, where 1 CAD = 0.67 Euro (EUR)) and $14 081.45/pt per cycle. The median number of cycles was 15. The predominant cost driver was the cost of chemotherapy accounting for an average of $179 332.78/pt or $12 419.17/pt per cycle. Carfilzomib acquisition accounted for the majority of chemotherapy costs – $162 471.65/pt or $11 251.50/pt per cycle. Fifty‐six percent (56%) of patients had at least one hospitalization during the trial period with an average cost of $12 657.86 per hospitalization. Three patients developed thrombotic microangiopathy (TMA) with an average cost of $18 863.32/pt including the cost of hospitalizations and therapeutic plasma exchange. Conclusions High‐dose wKCD is an active triplet regimen for relapsed and refractory multiple myeloma (RRMM) associated with reduced total cost compared with twice‐weekly carfilzomib‐based regimens.

show abstract

Section: Discussionmentioning

confidence: 99%

A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma

Monteith

Venner

Cheung

et al. 2021

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…The imputed value of foreg or services become inefficient or are withdrawn from production on account of morbidity or premature mortality is widely regarded as an indirect cost [21]. Usually, the key stakeholders consider the direct medical costs only [22][23][24], but for full picture we also need to consider the indirect costs [25,26] paid by payers that create inevitable part of total costs evaluation.…”

mentioning

confidence: 99%

Economic aspects of multiple myeloma: real costs associated with disease in the Slovak Republic

Babela¹,

Didič²,

Smatana³

et al. 2021

neo

View full text Add to dashboard Cite

Health care costs are continuously increasing. Multiple myeloma represents approximately 1% of all malignancies and the 5-year prevalence is 230,000 patients on average. In addition, there is an annual incidence of 3.8/100,000 in Slovakia. In total economic burden assessment, it is important to focus not only on direct but also on indirect costs, including the lost productivity due to premature death. Based on the data and information obtained from the key stakeholders the Ministry of Health, the Ministry of Labor, the Social Insurance Agency, and NCZI, we provided the assessment of direct and indirect costs. The total cost of the disease for the model patient represents 409, from the diagnosis of MM to death. The major cost burden is associated with the treatment, 155,645 o premature death, 127,-of-illness studies provide an important view on the total burden of the disease in specific areas and are necessary for adequate decision-making process from the regulatory and reimbursement perspective. Key words: multiple myeloma; cost-of-illness; direct costs; indirect costs; burden of disease The expenses on healthcare are constantly rising. The protocols for diagnostics and treatment of variety of diseases are more sophisticated, containing various possibilities of medical imaging, new surgical practices, new drugs and all this together leads to continual increases in costs. Diagnostics and treatment of patients with multiple myeloma (MM) represents no exception [1]. Worldwide, the MM accounts for approximately 1% of all cancers and is the 2nd most common hematologic malignancy with an estimated 24,280 to 30,330 new cases and 12,650 deaths to occur for 2016 [2-5]. Additionally, the 5-year prevalence is approximately 230,000 patients [6]. In the Western world, the age-standardized incidence has been reported to be approximately 5 cases/100,000 [7, 8]. The median age of patients at diagnosis is approximately 66-70 years with 37% of patients being younger than 65 years of age [3, 9]. MM is extremely rare in those less than

show abstract

What are the Real Indirect Costs Associated with Multiple Myeloma: Model Patient Analysis From Slovak Republic

Cited by 2 publications

References 0 publications

A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma

A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma

Economic aspects of multiple myeloma: real costs associated with disease in the Slovak Republic

Contact Info

Product

Resources

About